Conditions such as sepsis, HLH, and CRS, especially in the context of chimeric antigen receptor (CAR) T-cell therapy, are typically characterized by markedly elevated IL-6 levels [2]. This evidence concerns the gene IL6 and hemophagocytic syndrome.